Chemical Toolkit for PARK7: Potent, Selective, and High-Throughput

14Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The multifunctional human Parkinson's disease protein 7 (PARK7/DJ1) is an attractive therapeutic target due to its link with early-onset Parkinson's disease, upregulation in various cancers, and contribution to chemoresistance. However, only a few compounds have been identified to bind PARK7 due to the lack of a dedicated chemical toolbox. We report the creation of such a toolbox and showcase the application of each of its components. The selective PARK7 submicromolar inhibitor with a cyanimide reactive group covalently modifies the active site Cys106. Installment of different dyes onto the inhibitor delivered two PARK7 probes. The Rhodamine110 probe provides a high-throughput screening compatible FP assay, showcased by screening a compound library (8000 molecules). The SulfoCy5-equipped probe is a valuable tool to assess the effect of PARK7 inhibitors in a cell lysate. Our work creates new possibilities to explore PARK7 function in a physiologically relevant setting and develop new and improved PARK7 inhibitors.

Cite

CITATION STYLE

APA

Jia, Y., Kim, R. Q., Kooij, R., Ovaa, H., Sapmaz, A., & Geurink, P. P. (2022). Chemical Toolkit for PARK7: Potent, Selective, and High-Throughput. Journal of Medicinal Chemistry, 65(19), 13288–13304. https://doi.org/10.1021/acs.jmedchem.2c01113

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free